Skip to content

Reversible Monoacylglycerol Lipase (MAGL) Inhibitors for Neurodegenerative Pathologies and Tumour Treatment

A new class of monoacylglycerol lipase (MAGL) inhibitors distinguished by reversible and powerful mechanism of action

Published: 24th November 2022
Reversible Monoacylglycerol Lipase (MAGL) Inhibitors for Neurodegenerative Pathologies and Tumour Treatment
Source: SciePro, stock.adobe.com/uk/222960706, stock.adobe.com
IP Status
  • Patented
  • Know-how based
Seeking
  • Commercial partner
  • Licensing
  • Seeking investment
  • Development partner